AB Clinical Trials — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$111,069	6
2024	Research	$126,943	3
2023	Research	$114,174	5
2022	Research	$148,248	2
2021	Research	$60,909	14
2020	Research	$124,940	18
2019	Research	$26,294	4

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $582,767 18 payments
AbbVie, Inc. $91,753 24 payments
AstraZeneca Pharmaceuticals LP $38,059 10 payments

Studies the money was for Research payments · program years 2019–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $253,928 5 payments
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $162,935 4 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $144,015 4 payments
M16-100 $71,991 13 payments
A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $25,916 6 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $19,762 11 payments
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $12,143 4 payments
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C $11,462 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $4,239 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $3,783 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.